Please enable JavaScript.
Coggle requires JavaScript to display documents.
covid 19 vaccines - Coggle Diagram
covid 19 vaccines
-
CDC recommends that everyone 6 months of age and older complete the primary COVID-19 vaccination schedule and that everyone 5 years of age and older receive booster doses of COVID-19 vaccines. 19, when eligible.
People with moderate or severe immunosuppression have specific recommendations regarding COVID-19 vaccines, including booster doses. Learn more about COVID-19 vaccination recommendations for people with moderate or severe immunosuppression.
With the COVID-19 Vaccine Booster Help Tool, you can find out if and when you're due for a booster dose to keep up with your COVID-19 vaccines.
The following Recommendations about COVID-19 vaccines and boosters may be updated as CDC receives more recent data on vaccine safety and effectiveness, including data on their effectiveness over time and against new variants. .
At the end of December 2019, a new coronavirus (SARS-CoV-2) was identified as the causal agent of a new respiratory disease called COVID-19 by the WHO. Its symptoms include fever, dry cough and shortness of breath. These symptoms are generally mild, although they can be fatal in older adults and patients with comorbidities. A bibliographic search was carried out in Pubmed and Clinical Key where 22 articles were selected according to the inclusion criteria. SARS-CoV-2 belongs to the Betacoronavirus genus and has genomic similarities to SARS-CoV and MERS-CoV. The SARS-CoV-2 virion consists of a nucleocapsid and an outer envelope composed of major and accessory structural proteins. Its genetic material consists of a single-stranded RNA chain of positive polarity, in which important proteins for its transcription and replication are encoded. The SARS-CoV-2 infection mechanism begins with the binding of the virion to a host cell receptor (ACE2) and its subsequent entry by endocytosis. The viral RNA genome is released into the cytoplasm where the proteins necessary for the production of structural proteins and for the replication of its genetic material are transcribed and translated. Subsequently, the replicated RNA associates with the nucleocapsid and assembles together with the structural proteins to form the viral particles that will be released from the infected cell. The immune system copes with viral infection by recognizing pathogen-associated molecular patterns (PAMPs) by innate immunity and by the action of T and B lymphocytes by humoral immunity. Knowledge of the genetic and molecular bases of SARS-CoV-2 makes it possible to visualize the possibility of establishing pharmacological treatments or developing vaccines to control and reduce the pathogenic effects of the disease.
People 6 months to 64 years of age, especially men 12 to 39 years of age, may consider receiving a 2nd main dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna) 8 weeks later of the 1st dose.
Is 90% efficiency better than 70% efficiency? The answer seems obvious, but it's not that easy. Simple explanations do not usually get along with science. As inevitable as the preference for the vaccine that has published the highest percentage in its studies may seem, they are neither comparable figures nor do they accurately reflect the risk that each individual has of suffering from covid after inoculation. Experts insist that any of the approved ones is good and safe.
The federal agency issued its decision after a thorough review of clinical trials and its manufacturing data, which show that the vaccine is 93% effective in preventing COVID-19 and 98% effective in preventing severe forms of COVID-19. the illness.